Evidence map›Paper›PMID 37467062›Full record

ArticleThe Journal of physiology2023

MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy.

Mitchell C Lock, Kimberley J Botting, Beth J Allison, Youguo Niu, Sage G Ford, Michael P Murphy, Sandra Orgeig, Dino A Giussani, Janna L Morrison

Open access · hybridAbstract read
In one paragraph

Article in The Journal of physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Guidelines for in vivo models of developmental programming of cardiovascular disease risk.American journal of physiology. Heart and circulatory physiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Mitchell C LockEarly Origins of Adult Health Research Group, Health and Biomedical Innovation, UniSA: Clinical and Health Science, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-3594-1455
Kimberley J BottingDepartment of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK.
Beth J AllisonDepartment of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1060-513X
Youguo NiuDepartment of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK.ORCID 0000-0002-8843-9952
Sage G FordDepartment of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK.
Michael P MurphyMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Sandra OrgeigUniSA: Clinical and Health Science, University of South Australia, Adelaide, South Australia, Australia.
Dino A GiussaniDepartment of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1308-1204
Janna L MorrisonEarly Origins of Adult Health Research Group, Health and Biomedical Innovation, UniSA: Clinical and Health Science, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0002-8602-8519
University of Cambridge · GBUniversity of South Australia · AU

Funding

British Heart Foundation RG/17/8/32924Medical Research Council MC_UU_00028/4
6 · The paper itself

Abstract

Chronic fetal hypoxaemia is a common pregnancy complication that increases the risk of infants experiencing respiratory complications at birth. In turn, chronic fetal hypoxaemia promotes oxidative stress, and maternal antioxidant therapy in animal models of hypoxic pregnancy has proven to be protective with regards to fetal growth and cardiovascular development. However, whether antenatal antioxidant therapy confers any benefit on lung development in complicated pregnancies has not yet been investigated. Here, we tested the hypothesis that maternal antenatal treatment with MitoQ will protect the developing lung in hypoxic pregnancy in sheep, a species with similar fetal lung developmental milestones as humans. Maternal treatment with MitoQ during late gestation promoted fetal pulmonary surfactant maturation and an increase in the expression of lung mitochondrial complexes III and V independent of oxygenation. Maternal treatment with MitoQ in hypoxic pregnancy also increased the expression of genes regulating liquid reabsorption in the fetal lung. These data support the hypothesis tested and suggest that MitoQ as an antenatal targeted antioxidant treatment may improve lung maturation in the late gestation fetus. KEY POINTS: Chronic fetal hypoxaemia promotes oxidative stress, and maternal antioxidant therapy in hypoxic pregnancy has proven to be protective with regards to fetal growth and cardiovascular development. MitoQ is a targeted antioxidant that uses the cell and the mitochondrial membrane potential to accumulate within the mitochondria. Treatment of healthy or hypoxic pregnancy with MitoQ, increases the expression of key molecules involved in surfactant maturation, lung liquid reabsorption and in mitochondrial proteins driving ATP synthesis in the fetal sheep lung. There were no detrimental effects of MitoQ treatment alone on the molecular components measured in the present study, suggesting that maternal antioxidant treatment has no effect on other components of normal maturation of the surfactant system.

Indexed as

AntioxidantsHypoxiaOrganophosphorus CompoundsAnimalsFemaleHumansInfant, NewbornLungPregnancySheepSurface-Active AgentsUbiquinoneAntioxidantsmitoquinoneOrganophosphorus CompoundsSurface-Active AgentsUbiquinoneantioxidantfetal growth restrictionfetushypoxialung developmentsurfactant

Identifiers

PMID37467062
PMCPMC10952154
OpenAlexW4384820616

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.